- Home
- SGMO vs ADAG Comparison
SGMO vs ADAG Comparison
Compare SGMO & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGMO
- ADAG
- Stock Information
- Founded
- SGMO 1995
- ADAG 2011
- Country
- SGMO United States
- ADAG China
- Employees
- SGMO N/A
- ADAG N/A
- Industry
- SGMO Biotechnology: Biological Products (No Diagnostic Substances)
- ADAG Biotechnology: Pharmaceutical Preparations
- Sector
- SGMO Health Care
- ADAG Health Care
- Exchange
- SGMO Nasdaq
- ADAG Nasdaq
- Market Cap
- SGMO 122.8M
- ADAG 110.8M
- IPO Year
- SGMO 2000
- ADAG 2021
- Fundamental
- Price
- SGMO $0.51
- ADAG $2.82
- Analyst Decision
- SGMO Strong Buy
- ADAG Strong Buy
- Analyst Count
- SGMO 7
- ADAG 2
- Target Price
- SGMO $5.29
- ADAG $7.00
- AVG Volume (30 Days)
- SGMO 5.2M
- ADAG 111.5K
- Earning Date
- SGMO 08-07-2025
- ADAG 08-12-2025
- Dividend Yield
- SGMO N/A
- ADAG N/A
- EPS Growth
- SGMO N/A
- ADAG N/A
- EPS
- SGMO N/A
- ADAG N/A
- Revenue
- SGMO $81,706,000.00
- ADAG $103,204.00
- Revenue This Year
- SGMO $21.24
- ADAG $9,789.15
- Revenue Next Year
- SGMO N/A
- ADAG $29.92
- P/E Ratio
- SGMO N/A
- ADAG N/A
- Revenue Growth
- SGMO 565.52
- ADAG N/A
- 52 Week Low
- SGMO $0.41
- ADAG $1.33
- 52 Week High
- SGMO $3.18
- ADAG $3.58
- Technical
- Relative Strength Index (RSI)
- SGMO 44.92
- ADAG 68.31
- Support Level
- SGMO $0.47
- ADAG $2.11
- Resistance Level
- SGMO $0.56
- ADAG $2.45
- Average True Range (ATR)
- SGMO 0.03
- ADAG 0.23
- MACD
- SGMO -0.00
- ADAG 0.04
- Stochastic Oscillator
- SGMO 32.31
- ADAG 67.83
About SGMO Sangamo Therapeutics Inc.
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.
About ADAG Adagene Inc.
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development, and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity, as highlighted by the company's immunotherapy pipeline.